Physician profile
Brad Giarrusso
NPI 1104844455
$4,420.72
in general payments reported to CMS, 2019-2025
32 companies · $571 in 2025
The $571 reported for 2025 was more than what 76% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $665 · 2020: $425 · 2021: $909 · 2022: $895 · 2023: $628 · 2024: $328 · 2025: $571.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,527.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,527.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $586.36 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $499.39 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $327.57 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $299.62 | 2019-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $291.22 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $275.02 | 2019-2023 | Verquvo, Belsomra |
| Janssen Pharmaceuticals, INC | $273.18 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $263.16 | 2019-2024 | Trintellix |
| Abbvie INC. | $205.18 | 2021-2025 | |
| Amgen INC. | $159.88 | 2019-2021 | |
| Supernus Pharmaceuticals, INC. | $154.71 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $153.57 | 2020-2025 | Zoryve |
| Glaxosmithkline, LLC. | $133.59 | 2019-2025 | Shingrix, Arexvy |
| Teva Pharmaceuticals USA, INC. | $131.45 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $128.27 | 2019-2025 | Breztri, Airsupra |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $90.55 | 2022-2024 | Freestyle Libre 3 |
| Xeris Pharmaceuticals, INC. | $57.11 | 2021-2025 | Keveyis |
| Daiichi Sankyo INC. | $43.75 | 2022 | |
| Sanofi Pasteur INC. | $36.18 | 2025 | |
| Adlon Therapeutics L.P. | $35.62 | 2021 | |
| Ironshore Pharmaceuticals INC. | $34.91 | 2019 | |
| Novartis Pharmaceuticals Corporation | $31.42 | 2021-2022 | |
| Currax Pharmaceuticals LLC | $28.72 | 2020-2021 | |
| Allergan, INC. | $27.75 | 2019-2020 | |
| Shire North American Group INC | $24.84 | 2019 | |
| Hikma Pharmaceuticals USA | $23.16 | 2019 | |
| Azurity Pharmaceuticals, INC. | $20.39 | 2023 | Edarbi |
| Axsome Therapeutics, INC. | $20.01 | 2023 | Auvelity |
| Dexcom, INC. | $19.76 | 2025 | Dexcom G6 Transmitter |
| Neos Therapeutics, LP | $17.54 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $14.73 | 2022 | |
| Amarin Pharma, INC. | $12.11 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brad Giarrusso listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.